Cialis European Label Changed to Include Effectiveness up to 36 Hours

Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS) announced today that the European Commission has adopted changes to the European label for Cialis® (tadalafil), Lilly ICOS' oral PDE5 inhibitor for the treatment of erectile dysfunction (ED). The new label indicates that Cialis may be effective for up to 36 hours after taking the tablet, which makes it generally consistent with product labelling throughout the world, including in the United States, where Cialis was approved late last year.

"In the year that Cialis has been available in Europe, we have seen that men and their partners appreciate Cialis because it gives a man and his partner a broad window of opportunity so they can choose the moment for intimacy that is right for them," said Mark Barbato, executive director and product team leader, the Primary Care Products Group, Lilly. "This label change, to 36 hours, is an important milestone for Cialis because the European label is now consistent with other labels around the world."

"Product labeling worldwide reinforces how Cialis is different from other oral ED tablets," said Paul Clark, ICOS Chairman and Chief Executive Officer. "We believe men and their partners understand and appreciate the attributes of Cialis and we see them voting with their prescriptions. The market share for Cialis in some European countries exceeds 25 percent."

European Label Changes

The European label change became effective on January 27, 2004 when it was adopted by the European Commission. The European Committee for Proprietary Medicinal Products (CPMP), issued a positive opinion on the label update in October. The CPMP, comprised of regulators from the European Union countries, based its opinion on two placebo-controlled studies that were designed to measure the effectiveness of Cialis at 24 and 36 hours after taking the tablet. It also considered an integrated analysis of 11 studies to determine the effectiveness of Cialis in men with ED at all time points they chose to have intercourse from 30 minutes to 36 hours after dosing.(2) In the analysis of 580 men taking 20 mg Cialis, who attempted sexual intercourse between 12 and 24 hours after dosing, 73 percent of intercourse attempts were successful in response to sexual stimulation. Cialis studies were not designed to assess multiple intercourse attempts after a single dose. The new EU label also includes new safety information including updated dosing instructions for patients with liver and kidney impairments.

Labelled Duration of Cialis Now Globally Consistent

Independent Study Shows Men May Prefer Extended Period of Effectiveness

The importance of the duration of effectiveness is emphasized by a recent clinical study involving Cialis and assessing patient preference versus Viagra® (sildenafil citrate). The independent study, conducted by recognized experts in the field, will be presented at the 4th World Congress on the Aging Male (WCAM) later this month. The study showed that more former Viagra users preferred Cialis to Viagra(3). In this study, men were also asked which treatment they would choose to continue to take after the trial. The results showed that 62 percent of men who had used both drugs chose to continue with Cialis, compared to 20 percent who opted for Viagra.